Trial reportAnnals of surgical oncology2026
Two-Year Outcomes after Direct-to-Surgery in Good Prognosis Margin-Clear Stage II or III Rectal Cancer: The QuickSilver Study.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with clinical Stage II or III rectal cancer routinely receive neoadjuvant radiotherapy and chemotherapy. But pelvic magnetic resonance imaging may identify patients who can safely avoid neoadjuvant treatments. We evaluated 2-year oncologic outcomes for patients with "margin-clear" Stage II or III rectal cancer going directly to a planned low anterior resection. PATIENTS AND
methodsThis prospective, non-randomized, phase II trial was performed at 12 high-volume hospitals across Canada. Patients proceeded directly to a planned low anterior resection if they met the staging magnetic resonance imaging (MRI) criteria for "good prognosis" rectal cancer, including distance > 1 mm between primary tumor, tumor nodule, or positive mesorectal lymph node and the mesorectal fascia. Primary outcomes were 2-year rates of local recurrence, disease free survival, and overall survival.
resultsFrom 30 September 2014 to 31 December 2019, 139 patients met the inclusion criteria and were recruited for the study. Final pathology was Stage 1 in 59 (42%) patients and Stage II/III in 80 (58%). For the 80 Stage II or III patients, 2-year rates for local recurrence, disease free and overall survival were 1% (95% confidence interval [CI] 0-6.8), 85% (95% CI 75.3-92.0), and 99% (95% CI 93.2-100), respectively. Only 8% (6/80) (95% CI 2.8-15.6) received adjuvant radiotherapy. Preoperative staging MRI findings over-staged 30 of 59 pathology-confirmed Stage I patients (51%) (95% CI 37.5-64.1) to a clinical Stage II or III status.
conclusionsAmong patients planned for a low anterior resection and with MRI criteria predicting margin-clear Stage II or III rectal cancer, a direct-to-surgery approach was associated with excellent 2-year oncologic outcomes and low use of radiation.
trial registrationISRCTN.com Identifier: ISRCTN05107772.
Indexed as
Identifiers
42310267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.